ARCA biopharma

165 articles with ARCA biopharma

• GENETIC-AF PHASE 2B CLINICAL TRIAL ATRIAL FIBRILLATION BURDEN (AFB) RESULTS PRESENTED AT AMERICAN HEART ASSOCIATION 2018 SCIENTIFIC SESSIONS

  11/12/2018

  ARCA biopharma (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that data from the Atrial Fibrillation Burden (AFB) substudy of the Phase 2B GENETIC-AF clinical trial were presented November 11, 2018 in a poster session at the American Heart Association 2018 Scientific Sessions in Chicago.

• ARCA BIOPHARMA SUBMITS SPECIAL PROTOCOL ASSESSMENT REQUEST TO FDA FOR GENCARO PHASE 3 ATRIAL FIBRILLATION CLINICAL TRIAL

  9/18/2018

  ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA). 

• ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update

  8/9/2018

  ARCA biopharma, Inc. reported financial results for the quarter ended June 30, 2018.

• 

  ARCA Biopharma Shares Soar After Positive FDA Meeting

  8/1/2018

  ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart failure (HF).

• ARCA Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting With FDA on Gencaro Development for Atrial Fibrillation

  7/31/2018

  Single Phase 3 trial may be sufficient for approval of atrial fibrillation indication

• Arca Biopharma Announces First Quarter 2018 Financial Results and Provides Corporate Update

  5/9/2018

  ARCA biopharma, Inc. reported financial results for the quarter ended March 31, 2018.

• 

  Shares Plunge as ARCA biopharma’s Gencaro Had Mixed Phase II Clinical Trial Results

  2/26/2018

  ARCA biopharma announced positive headline results from its Phase IIb clinical trial of Gencaro, but investors aren't buying the positive spin.

• ARCA Biopharma Selects TransPerfect’s Trial Interactive eTMF Solution

  2/2/2018

  ARCA Biopharma today announced that ARCA biopharma has selected TransPerfect’s Trial Interactive eTMF solution as their enterprise platform for clinical trials.

• ARCA biopharma Announces Completion of GENETIC-AF Phase IIB Clinical Trial

  1/8/2018

  ARCA expects to report top-line Phase 2B data in March 2018.

• ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

  11/16/2017

  The European patent, entitled “Methods and Compositions for Cardiovascular Diseases and Conditions,” provides protection for this novel approach to treating patients with cardiovascular disease and conditions.

• ARCA biopharma Announces Third Quarter 2017 Financial Results and Provides Business Update

  11/10/2017

  Cash, cash equivalents and marketable securities totaled $16.0 million as of September 30, 2017, compared to $23.5 million as of December 31, 2016.

• ARCA biopharma Announces Completion Of Enrollment For GENETIC-AF Phase IIb Clinical Trial

  8/16/2017

• ARCA biopharma Announces Genetic-Af Data And Safety Monitoring Board Recommendation To Complete Phase IIb Genetic-Af Clinical Trial Based On Efficacy And Safety Data In Phase IIb Interim Analysis

  8/10/2017

• ARCA biopharma Announces GENETIC-AF Data And Safety Monitoring Board Recommendation To Complete Phase 2B GENETIC-AF Clinical Trial Based On Efficacy And Safety Data In Phase IIB Interim Analysis

  8/10/2017

• ARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update

  8/4/2017

• ARCA biopharma Announces Database Lock For GENETIC-AF Phase IIB Interim Efficacy Analysis – DSMB Recommendation Anticipated In August 2017

  6/20/2017

• ARCA biopharma Announces First Quarter 2017 Financial Results And Provides Business Update

  5/15/2017

• ARCA biopharma Announces 200th Patient Randomized Into The GENETIC-AF Seamless Design Phase IIB/III Clinical Trial

  4/26/2017

• ARCA biopharma Announces Fiscal Year 2016 Financial Results And Provides Business Update

  3/22/2017

• ARCA biopharma Announces 175th Patient Randomized Into The GENETIC-AF Phase 2B/3 Clinical Trial

  3/6/2017